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Abstract Familial defective apolipoprotein B-100 (FDB) is 
caused by a single G-to-A substitution at nucleotide 10,708 lead- 
ing to an arginine to glutamine change at amino acid 3,500 of 
the apolipoprotein B-100 and thus, a reduced binding of the 
apolipoprotein B to the low density lipoprotein (LDL) receptor. 
In the present study, the prevalence of FDB in Switzerland was 
estimated, on the one hand, from a sample of 728 healthy volun- 
teers whose origin was spread out over the entire German, 
French, and Romansh speaking parts of the country, and, on the 
other hand, from 142 unrelated Swiss families with primary 
hypercholesterolemia comprising 520 individuals. Using poly- 
merase chain reaction (PCR)-based methods, three individuals 
were identified with the point mutation in the sample of volun- 
teers, equivalent to a prevalence of approximately 1/240 (90% 
confidence interval: 1.51 x 10-3-1.03 x 10-2). The frequency of 
FDB in the sample of hypercholesterolemic subjects was 7/142, 
yielding a prevalence of approximately 1/190 extrapolated to the 
general population (90% confidence interval: 2.63 x 10-3-9.17 x 
10-2). The combined prevalence based on both samples was 
1/209. Thus, the investigated point mutation was highly preva- 
lent in Switzerland and appeared to be more frequent than in 
other populations studied hitherto. Furthermore, the presence of 
the mutation was not necessarily associated with an elevation of 
serum cholesterol levels, particularly in young individuals. 
While in the non-affected volunteers cholesterol levels increased 
between the age of 19 and 23 years by 0.22 mmol/l or by 5.6% 
(P = 0.001), this phenomenon was even more pronounced in in- 
dividuals with FDB. The three volunteers with the point muta- 
tion demonstrated an increase in totd cholesterol concentrations 
by 1.30 mmol/l or by 25% within 2 years, suggesting that, in the 
early twenties, cholesterol concentrations increase markedly 
from normal to elevated levels. a Considering the estimated 
high prevalence and the relative ease of PCR-based tests, screen- 
ing for FDB may become a standard procedure in patients with 
suggested familial forms of hypercholesterolemia. - Miserez, A. R., 
R. Laager, N. Chiodetti, and U. Keller. High prevalence of 
familial defective apolipoprotein B-100 in Switzerland. J.  Lipid 
Res. 1994. 35: 574-583. 
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was recently identified in patients with moderately in- 
creased LDL cholesterol concentrations (1-3). This meta- 
bolic disorder was designated familial defective 
apolipoprotein B-100 (FDB). A markedly reduced (ap- 
proximately 32% of the normal) binding of LDL particles 
isolated from FDB patients to LDL receptors of cultured 
fibroblasts and a decrease of the clearance of LDL in tur- 
nover studies has been demonstrated in affected in- 
dividuals (1). FDB is caused by a single base substitution 
(G-to-A) at nucleotide 10,708 in exon 26 of the 
apolipoprotein B-100 gene (chromosome 2) creating an 
arginine to glutamine substitution at the codon for amino 
acid 3,500 of the mature apolipoprotein (4). The point 
mutation is transmitted as an autosomal codominant trait 
(2); clinical features in FDB patients may be similar to 
those in patients with familial hypercholesterolemia (FH) 
(5). The prevalence of FDB has been estimated to be 
1/500-1/700 in different populations (6-8). Individuals 
with FDB have been detected in Caucasians from the 
United States (2, 6, 9), Canada (6, 9), the United King- 
dom (7), Denmark ( 7 ) ,  Austria (6, lo), Germany (8, 
11-13), Italy (14), the Netherlands (13, 15, 16), South 
Africa (15, IS), Norway (16), Australia (16), and in a non- 
Caucasian (Chinese; 17) but up to now not in Caucasians 
from Finland (18), Russia (13), and Israel (19) nor in non- 
Caucasians from Japan (19). However, a direct assessment 
of the prevalence in a particular population based on a un- 
selected sample of subjects representative of the general 
population has not been carried out previously. Thus, the 
present study was performed to assess the prevalence of the 
point mutation in the general population of Switzerland 
from a sample of healthy volunteers and its confirmation by 
estimations from a sample of hypercholesterolemic individuals. 
Abbreviations: FDB, familial defective apolipoprotein B-100; PCR, . ~~ 
polymerase chain reaction; LDL, low density lipoprotein; FH, familial 
hvpercholesterolemia; SE buffer, sodium chloride-EDTA buffer. Defective binding Of low density lipoprotein (LDL) due .. 
to a specific structural defect of the apolipoprotein B-100 'To whom correspondence should be addressed 
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SUBJECTS, MATERIALS, AND METHODS 
Subjects 
Two groups of subjects were screened for the presence 
of FDB. The first group consisted of 728 unrelated healthy 
male individuals from the German, French, and 
Romansh speaking parts of Switzerland recruited for 
military service in August 1991. The three volunteers posi- 
tive for the point mutation were reexamined in August 
1993 to confirm the results of the initial cholesterol deter- 
minations and to screen their families. 
The second group consisted of 520 individuals from 142 
unrelated families with suggested inherited forms of 
hypercholesterolemia which were diagnosed in the 
presence of LDL cholesterol levels exceeding the 95th per- 
centile (corrected for age and gender) in the index patient 
and in at least three family members of two generations. 
Among the 142 families with hypercholesterolemia, 102 
were from northern, 19 from southwestern, 5 from 
western, and 16 from eastern parts of Switzerland. There 
were 296 hypercholesterolemic (142 unrelated index pa- 
tients and 154 relatives) and 224 normocholesterolemic fa- 
mily members. 
All subjects gave their informed consent according to 
the Helsinki/Tokyo declaration to participate in this 
study. The study was approved by the ethical committee 
of our hospital. 
Materials 
Thennus aquaticus polymerase and nucleotides were pur- 
chased from Perkin Elmer Cetus Corporation (Norwalk, 
CT). Oligonucleotides were synthesized on an Applied 
Biosystems DNA synthesizer model 380 (Applied Bio- 
systems, Foster City, CA) at the Biocenter, University of 
Basel, Switzerland. DNA was amplified using Cambio In- 
telligent Heating Blocks, model 2024 (Cambio, Cam- 
bridge, UK). Agarose was purchased from Bio-Rad 
(Richmond, CA) and restriction endonucleases were from 
Pharmacia LKB (Uppsala, Sweden). [(Y-~*P] dCTP, mul- 
tiprime DNA labeling systems, and Hybond NTM nylon 
membranes were obtained from Amersham International 
(Buckinghamshire, UK). The probe for analyzing the 
LDL receptor gene was pLDLR-2HH1, containing a 1.9 
kb fragment of the full-length cDNA which hybridizes 
with exon 11 to exon 18 of the gene (20). 
Methods 
Lipoprotein analyses. Blood samples were drawn in all 
subjects of both groups 12 h postprandially. LDL 
cholesterol was determined after precipitation with hepa- 
rin and HDL cholesterol after precipitation with phos- 
photungstic acid and magnesium ions. Total, LDL, HDL 
cholesterol, and triglyceride concentrations were meas- 
ured in all the subjects at the same laboratory by en- 
zymatic colorimetric methods (Boehringer Mannheim, 
Germany) on a Hitachi analyzer model 737. 
DNA extraction method. Total genomic DNA was ex- 
tracted from white blood cells by the salting-out method 
(21) with the following modifications. Ten ml EDTA blood 
was mixed with 30 ml of an erythrocyte lysis buffer (155 
mM NH,Cl, 10 mM KHC03, 0.1 mM EDTA, pH 7.4), 
and left on ice for 1 h. The tubes were centrifuged (10 
min, 150 g, 4OC) and the cell pellet was resuspended in 30 
ml of sodium chloride-EDTA (SE) buffer (75 mM NaC1, 
25 mM EDTA, pH 8.0). The cells were centrifuged as 
described above and resuspended in 5 ml of the SE-buffer. 
Seventy-five ~1 of proteinase K (20 mg/ml) and 15 ~1 of 
RNAse A (10 mg/ml) were added. After mixing and ad- 
ding 250 pl of 20% SDS, cells were digested overnight at 
5OOC. Subsequently, SE-buffer was added to a total 
volume of 10 ml. Proteins were salted out using 2.8 ml of 
6 M NaCl and shaken vigorously for 15 sec, followed by 
centrifugation (15 min, 1000 g, 2OOC). The supernatant 
was transferred to another tube and precipitated with two 
volumes of absolute ethanol. The precipitated DNA 
strands were transferred to a 1.5 ml tube. DNA was once 
washed with 70% ethanol, twice with 100% ethanol, and 
dried overnight. Finally, DNA was resuspended in 0.5 ml 
of Tris-EDTA (TE) buffer (10 mM Tris-HC1 (pH 8.0), 1 
mM EDW) and measured spectrophotometrically at 260 nm. 
Zsting for the point mutation causing FDB. A combination 
of allele-specific and asymmetric PCR was used (22). 
With the help of two primers, an upper (UOL) and a 
lower oligonucleotide (LOL), a DNA strand of 0.320 kb 
in length containing the mutation site was amplified. 
Provided that the mutation was present in the template, 
a third allele-specific oligonucleotide (ASO), complemen- 
tary to the mutation, began to amplify additional DNA 
strands starting from the point mutation as soon as the 
concentration of the LOL was lower than that of the ASO. 
As the G-to-A substitution was 0.144 kb upstream to the 
5' end of the initially amplified DNA, the additional frag- 
ment was 0.144 kb in length. In all series, DNA from pa- 
tients with FDB confirmed by allele-specific oligomelting 
served as controls (8). All subjects with total cholesterol 
> 4.5 mmol/liter were tested individually in two indepen- 
dent runs and all reactions were carried out in duplicate. 
Blood samples from subjects with cholesterol levels 5 4.5 
mmol/liter were pooled (25 samples) and screened using 
the method of Ruzicka et al. (23). In the case of positive 
pools, DNA from each subject contributing to the pool 
was extracted and tested individually. 
Major rearrangments and cosegregation analysis at the LDL 
receptor gene locus in families with FDB. To exclude major 
rearrangements at the LDL receptor locus in subjects 
with FDB, Southern blot investigations using the restric- 
tion enzyme Xba I were performed (24, 25). Five pg 
genomic DNA was digested for 24 h with 10 U Xba I and 
subjected to electrophoresis. After denaturation of the 
gels, DNA fragments were transferred to nylon mem- 
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branes and fixed by UV-light radiation. The cDNA B a m H  
I-fragment of the LDL receptor gene probe was excised 
as described by Schuster et al. (26) and 5'-labeled using 
random oligonucleotide primers and [ c x - ~ * P ] ~ C T P  (3,000 
Ci/mmol). Membranes were hybridized at 65OC for 24 h, 
washed two times for 30 min at 65OC in 1 x SSC (150 
mM NaCl, 15 mM sodium citrate) and 0.1% SDS, and 
exposed to Kodak X-Omat AR-5 films for 24-72 h. In all 
FDB families, haplotypes using eight restriction fragment 
length polymorphisms (RFLPs) at the LDL receptor 
locus (Tag I, Stu I, Hinc 11, Ava 11, A p a L  I 5', Pvu 11, 
Nco I, and A p a L  I 3')  were constructed according to the 
methods described elsewhere (27). Cosegregation analyses 
between the individuals with hypercholesterolemia and 
the corresponding LDL receptor haplotypes were per- 
formed. 
Apolipoprotein E restriction isogping. Restriction isotyping 
of human apolipoprotein E was performed by gene am- 
plification and cleavage with Hha I as described by Hixson 
and Vernier (28). 
Statistical methods. The confidence interval of the fre- 
quency of the mutation in the sample of volunteers was 
calculated using methods based on a Poisson distribution 
since NP < 5, whereas N is the sample size and P is the 
frequency of the point mutation in the sample (29, 30). 
The prevalence of the mutation assessed from the sample 
of families with hypercholesterolemia was estimated ac- 
cording to the method described by Innerarity et al. (6). 
Data from the Lipid Research Clinics (LRC) study 
(48,482 individuals from North America; 31) were used to 
compare the present findings with a previous study (6); 
data from the MONICA study (3,341 individuals from 
Switzerland; 32) were used to estimate the prevalence of 
FDB in Switzerland. The prevalence of the mutation was 
calculated by the maximum likelihood estimation using 
data from both samples. Subjects from the sample of 
volunteers were stratified into three groups with respect to 
their age (19-20.9 years, 21-22.9 years, and 23-29 years). 
Differences of mean total cholesterol concentrations 
among the three age groups were calculated by the Scheff6 
F-test and by one-way analysis of variance (ANOVA). 
Fisher's exact test was used to compare frequencies of the 
mutation in samples from different populations. All calcu- 
lations were performed on DEC and Macintosh computers. 
Fig. 1. The map shows the domiciles of the 728 volunteers participating in,this study (closed circles represent one individual, open circles represent 
more than one subject whereas the areas of the circles are proportional to the number of volunteers originating from the respective city). The distribu- 
tion of the domiciles of the volunteers reflects the Swiss population density at December 31 1990 (Bundesamt fur Landestopografie (1992), CH-3084 
Wabern, Switzerland) quite exactly. Closed squares represent the domiciles of the three individuals positive for the mutation. 
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Fig. 2. Total serum cholesterol levels of 728 volunteers (closed parts of the bars: subjects with the point mutation). 
RESULTS 
Characteristics of the healthy volunteers 
Fig. 1 represents the geographic origin of the inves- 
tigated volunteers in Switzerland spread out over the en- 
tire country except the small Italian speaking part south 
of the Alps. Most (91.8%) of the volunteers were between 
19 and 22 years old and the median age was 20.5 years 
(range 19 to 29 years). Fig. 2 shows the frequency distri- 
bution of the cholesterol values in the investigated volun- 
teers. Mean cholesterol of the 728 volunteers (k SEM) 
was 3.98 k 0.03 mmol/liter. The mean cholesterol con- 
centration in the 501 normocholesterolemic volunteers of 
the age of 19-20.9 years (group 1) was 3.90 f 0.03 
mmol/l, in the 193 volunteers of 21-22.9 years (group 2) 
4.12 k 0.06 mmol/l, and in the 26 volunteers of 23-29 
years (group 3) 4.47 k 0.18 mmol/l, respectively. 
Stratification of the normocholesterolemic 720 volunteers 
with respect to their age revealed significant differences of 
total cholesterol concentrations between group 1 and 2 (A 
= 5.6%, P = O.OOll), between 1 and 3 (A = 14.6%, 
P = 0.0003), and between group 2 and 3 (A = 8.5%, 
P = 0.0437). The overall difference among the three 
groups assessed by one-way ANOVA was also significant 
(P = 0.0001). In 8 of the 728 volunteers total cholesterol 
levels exceeded the 95th percentile (5.90 mmol/l). 
Characteristics of subjects from families with primary 
hypercholesterolemia 
The mean pretreatment level of total cholesterol of the 
296 hypercholesterolemic members (k SEM) from the 
142 families was 8.95 k 0.14 mmol/l and mean LDL 
Familial Defective Apolipoprotein B-1 00 
G to A Substitution 
- 1.353 kb 
- 0.603 kb 
Q.32Qkb- - 0.281 kb - 0.118kb 0.144 kb - 
2 
A A A A G G G G A A  
Fig. 3. Results of allele-specific asymmetric PCR. All reactions were performed in duplicate. 
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cholesterol was 7.09 f 0.18 mmol/l. Mean total and LDL 
cholesterol of the 224 subjects not affected by primary 
hypercholesterolemia from these families were 5.57 0.10 
mmol/l and 3.61 rl. 0.11 mmol/l, respectively. 
Frequency of FDB in the two samples 
Fig. 3 presents the result of asymmetric allele-specific 
PCR and agarose gel electrophoresis (all reactions 
carried out in duplicate) of four of the volunteers, from 
whom two were positive for the mutation, and one subject 
with proven FDB due to the G-to-A substitution which 
served as a control (kindly provided by H. Schuster, 
Munich). 
From the sample of 728 unrelated, healthy volunteers, 
three individuals living in different regions of Switzerland 
were identified as carrying the point mutation. All three 
were members of obviously autochthonous Swiss families. 
Reconstruction of the origin of the three families over four 
generations revealed no ancestors who had immigrated 
from other countries except the unaffected father (11112) 
of the volunteer from the H-family (Fig. 4). Surnames 
and maiden names of the family members were typical for 
the respective geographical regions of Switzerland where 
the families lived. Total cholesterol concentrations ini- 
tially determined in the three individuals positive for the 
point mutation were 4.33, 5.92, and 6.31 mmol/l, respec- 
tively. Two years after the first evaluation, the three in- 
dividuals with the point mutation were reexamined. Fig. 
4 presents the pedigrees of the three families of these 
volunteers. In the volunteer with an initially normal 
D-Family 
III 
I V  
B-Family 
I V  
H-Family 
Fig. 4. Families of the three volunteers positive for the point mutation. 
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cholesterol concentration (4.33 mmol/l; D-family, W l ) ,  
the determinations 2 years later revealed total cholesterol 
and LDL cholesterol concentrations above the 95th per- 
centile (6.05 and 4.29 mmol/l, respectively) corresponding 
to an approximately 40% increase compared to the initial 
cholesterol value. Elevated total and LDL cholesterol con- 
centrations had also been demonstrated in the volunteer's 
father (111/2): 10.60 and 8.22 mmolll, respectively. Total 
cholesterol concentrations (all determined in the same 
laboratory) of the younger brother of the volunteer (IV/2) 
were strikingly inconstant between the ages 15 and 21 
years, sometimes clearly elevated: 6.94 (1989), 7.59 (1992), 
and 6.71 mmol/l (1992), sometimes in the normal range: 
5.44 mmol/l (1989), corresponding to a 40% difference. 
Very unstable cholesterol concentrations were also de- 
tected in the second volunteer (B-family; Fig. 4): 6.10 
mmol/l (1988), 5.89 mmol/l (1991), 4.60 mmol/l (1993), 
5.30 mmol/l(l993), 6.56 mmol/l (1993), corresponding to 
a 43% difference within one year. In the third volunteer 
carrying the point mutation (H-family), total cholesterol 
concentrations also increased clearly (from 6.31 to 7.81 
mmol/l) during the 2 years corresponding to a 24% in- 
crease. The absence of hypercholesterolemia in the first 
volunteer (D-family) at the age of 20 years was not cor- 
related to the apolipoprotein E3/E3 genotype as this geno- 
type was also present in his hypercholesterolemic father 
(III/2) and in his hypercholesterolemic brother (IV/2). 
Reexamination of the three volunteers and their families 
confirmed the presence of the point mutations in the three 
probands, in the father (III/2) and the brother (IV/2) of 
the first volunteer (D-family), in one of the two brothers 
(IV/3) of the second volunteer (B-family), and in the 
mother (III/3) and the sister (IV/2) of the third volunteer 
(H-family). 
In seven of the 142 unrelated families with primary 
hypercholesterolemia and in 20 from 520 individuals 
studied, the defective apolipoprotein B-100 was identified. 
In all these families, there were no major rearrangements 
at the LDL receptor locus detectable using Xba I nor were 
there families with a cosegregation between hyper- 
cholesterolemic phenotypes and a particular LDL recep- 
tor haplotype. The mean pretreatment total and LDL 
cholesterol concentrations in the 20 subjects with the 
point mutation were 9.16 f 0.41 mmol/l and 7.10 + 0.30 
mmol/l, respectively. 
Estimation of the prevalence of FDB in the general 
population 
The frequency of FDB in the sample of healthy volun- 
teers was 3/728, 4.12 x or approximately 1/240 (90% 
confidence interval: 1.51 x 10-3-1.03 x or 1/661-1/97, 
respectively). The frequency of FDB in the sample of fa- 
milies with primary hypercholesterolemia was 7/142 (1/20) 
or 4.93 x (90% confidence interval 2.53 x 
8.82 x lo-* or U39-1/12). Using data of the LRC study 
comprising 48,482 North American individuals (31), the 
prevalence of FDB would be 2.38 x 10-3 or approximately 
1/420. However, mean cholesterol levels in individuals 
from Switzerland (32) were, depending on age and sex, 
15.5%-19.7% higher than in the individuals of the LRC 
study. Thus, if data of the MONICA study from Switzer- 
land were used, the prevalence in the general population 
was 5.20 x 10-3 or approximately 1/190 (90% confidence 
interval: 2.63 x 10-3-9.17 x 10-3 or 1/381-1/109; Table 1). 
The estimation based on both samples (volunteers and 
families with primary hypercholesterolemia) was 4.79 x 
or 11209. The population of the German, French, and 
Romansh speaking parts of Switzerland (without the 
TABLE 1 .  Estimation of the prevalence of familial defective apolipoprotein B-100 in Switzerland 
extrapolated from data of the MONICA study (Switzerland) 
Number of Individuals 
~ ~ ~ 
This Study MONICA Study" 
Age Sex LDL Cholesterol Probands Total Group Total Frequency' 
YT mmol/l 
25-34 M > 4.97 1 9 24 3,341 0.000798 16 
35-44 M > 5.45 1 18 51 3,341 0.00084805 
45-54 M > 5.64 1 18 49 3,341 0.0008 1479 
55-64 M > 5.47 1 15 37 3,341 0.00073830 
45-54 F > 5.27 1 1 7  43 3,341 0.00075708 
55-64 F 4.99-5.65 1 25 52 3,341 0.00062257 
55-64 F > 5.65 1 1 7  35 3,341 0.00061 623 
Total 0.00519518 
'Burnand et al. I993 (32). 
'Frequencies were calculated according to the formula of Innerarity et al. 1990 (6): (ProbanddThis Study 
Total) x (Group/MONICA Study Total). 
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Italian speaking part: 290,000 inhabitants) consisted at 
December 31st 1991 of 6,802,900 inhabitants (data of the 
Bundesamt fur Statistik, CH-3003 Berne, Switzerland, 
1992). Thus, assuming a prevalence of 1/209, approxi- 
mately 32,500 individuals with this particular point muta- 
tion are expected in the German, French, and Romansh 
speaking population of Switzerland. 
Table 2 presents the comparison of the present data 
with the estimated prevalence of FDB in other popula- 
tions. The frequency of FDB in hypercholesterolemic sub- 
jects from Switzerland was significantly higher than in the 
sample from Finland but there was no significant differ- 
ence to the FDB frequency in hypercholesterolemic sub- 
jects (FH or type IIa hyperlipidemia) from the United 
Kingdom or from Germany. 
DISCUSSION 
The sample of healthy volunteers originating from mili- 
tary trainees was not selected as, in Switzerland, all male 
individuals after the age of 19 years are drafted. The dis- 
tribution of the domiciles of the volunteers was very simi- 
lar to that of the general population with the exception of 
the small Italian speaking part south of the Alps from 
which no subjects were available for investigation (Fig. 1). 
Thus, since the disorder studied is caused by a germ line 
mutation located on an autosomal chromosome, the fre- 
quency of the point mutation in the present sample ap- 
pears to be representative of the prevalence in the general 
population. As hypercholesterolemia associated with FDB 
is often moderate (l), even in individuals homozygous for 
the mutation (33), and is rarely associated with coronary 
artery disease before the age of 50 years (5), the point mu- 
tation probably does not affect Darwinian fitness of these 
individuals. In a natural population such as the Swiss, a 
single gene mutation newly arisen in one parent runs a 
high risk of chance elimination in its immediate descen- 
dants. Probabilities for fixation or for extinction of neutral 
alleles arising by mutation can be calculated by equations 
of Kimura (34, 35). When a population is subdivided into 
isolate breedings of limited size (N), the ultimate proba- 
bility for fixation of neutral alleles over all isolates is 
P = qo, where qo is the initial frequency of a neutral al- 
lele. Assuming no selection and thus, equal Darwinian 
fitness of the subjects carrying the mutant allele, com- 
puter simulations of fixation and extinction of single gene 
mutants in a population of N = 100 with an initial 
q, = 1/(2N) = 5.0 x 
or U204 and a mean number of generations to fix the fre- 
quency of the mutant allele of t ,  = 394 (36). Thus, ap- 
proximately 10,000 years would be necessary for fixation 
of a mutant in a given population. As it has been demon- 
strated by Innerarity et al. (6), the probability that the 
mutation has occurred independently more than once is 
very low. Furthermore, a founder gene effect has previ- 
ously been assumed and it has been suggested that the 
mutation may have emerged in the common ancestors of 
a large number of Caucasian populations (6). As the G- 
to-A substitution at the apolipoprotein B-100 locus has not 
been detected among 552 hypercholesterolemic patients 
from the Finnish population (18) or in the St. Petersburg 
result in a final q = 4.9 x 
TABLE 2. Comparison of the prevalence of FDB due to the G to A mutation in different population samples 
CitylCountry 
Affected 












Total (combined prevalence) 
Innerarity et al. 1990 (6) 
Innerarity et al. 1990 (6) 
Innerarity et al. 1990 (6) 
Innerarity et al. 1990 (6) 
Innerarity et al. 1990 (6) 
Tybjrerg-Hansen et al. 1990 ( 7 )  
Tybjrerg-Hansen et al. 1990 (7) 
Tybjaxg-Hansen et al. 1990 (7) 
Schuster et al. 1990 (8) 









































"A: Estimated from hypercholesterolemic subjects; B: Estimated from subjects with atherosclerosis; C: Estimated from normocholesterolemic 
subjects; D: Pooled prevalence estimated from normo- and hypercholesterolemic subjects corrected using data of the LRC study (North America; 
48,482 individuals; 31); E: estimated from hypercholesterolemic subjects (type IIa hypfrlipoproteinemia) corrected using data of the MONICA study 
(Burnand et al. 1993; 32); F: Estimated from a sample of healthy male Swiss volunteers originating from the entire country. 
*P values (Fisher's exact test): significance levels of differences between the frequency of FDB in Swiss hypercholesterolemic subjects (711 42) and 
the frequencies in subjects from other populations. P values in parentheses: samples are not directly comparable. 
580 Journal of Lipid Research Volume 3 5 ,  1994 










area (13), it may be hypothesized that this base exchange 
may have arisen after the divergence of the Finnish and the 
other Caucasoid populations. From genetic distances be- 
tween the Finnish and the other European populations (37), 
this divergence is estimated to have occurred approximately 
10,000 to 20,000 years ago, in any case, clearly after the 
divergence of Caucasoid populations and Mongoloids 
which was approximately 41,000 years ago (37). On  the 
other hand, the finding of a similar prevalence of the point 
mutation in several European and American Caucasian 
populations and in a man of Chinese origin (17) as well 
as the finding of a prevalence which was (particularly in 
the Swiss) close to the theoretically expected frequency of 
a fixed gene (1/204), both suggest fixation of the mutant 
alleles in these populations. This supports the hypothesis 
that the mutation may be at least 10,000 years old and, if 
the mutation in this Chinese individual did not occur in- 
dependently, even more than 41,000 years old. 
However, it is a striking observation that only one mu- 
tation causing a defect of the binding site of the 
apolipoprotein B-100 has been described in detail since 
1986 up to now. This defect impairs the interaction be- 
tween the ligand, the apolipoprotein B-100, and the LDL 
receptor. At the LDL receptor locus itself, more than 150 
different mutations have been detected causing similar 
pathophysiologic changes resulting in elevated LDL 
cholesterol concentrations (38). Thus, it may be hypothe- 
sized that, in contrast to the situation at the LDL receptor 
locus (27), there is a very low mutation rate at the 
apolipoprotein B-100 locus, or mutations other than the 
base exchange at position 10,708 may be lethal during em- 
bryonic development. 
Total cholesterol values of the 728 healthy volunteers in- 
vestigated in this trial are well characterized by a Gaus- 
sian distribution (Fig. 2). Cholesterol concentrations in 
two of the three subjects identified as carrying the muta- 
tion were clearly increased compared with levels of in- 
dividuals at equal ages. However, the levels corrected for 
age and sex were lower than in FH patients reported in 
the literature (39) and only moderately elevated com- 
pared with three of the other six hypercholesterolemic in- 
dividuals from this sample. Furthermore, we did not an- 
ticipate detecting an individual with the point mutation 
but with a normal cholesterol concentration. Two years af- 
ter the first evaluation, the three volunteers identified as 
being affected were reexamined in order to confirm the 
results of the initial lipid determinations, to study the 
cosegregation between the point mutation and the clinical 
features within the families, and to confirm the autosomal- 
codominant trait of the mutation. 
The presence of hypercholesterolemia was not depen- 
dent on the apolipoprotein E genotypes, although the ini- 
tially normocholesterolemic volunteer in our study as well 
as the two normocholesterolemic individuals with the 
point mutation in the report of Gallagher and Myant (40) 
were homozygous for apolipoprotein E3. One of these two 
normocholesterolemic subjects reported in the literature 
was an 8-year-old boy with total and LDL cholesterol con- 
centrations of 3.6 and 2.7 mmol/l, respectively; the second 
was a 37-year-old man (5.0 and 3.4 mmol/l, respectively). 
The E3 phenotype is the most frequent one and thus, it 
may be by chance only that all the normocholesterolemic 
individuals with the point mutation described hitherto 
were homozygous for E3. Furthermore, other affected in- 
dividuals of this family were also homozygous for E3 and, 
nevertheless, hypercholesterolemic. 
Total cholesterol levels in the sample of healthy volun- 
teers were significantly higher in subjects of 21-22.9 years 
than of 19-20.9 years and this phenomenon was even 
more pronounced in the individuals with the point muta- 
tion causing FDB. The same mechanisms leading to an 
increase in the LDL cholesterol concentrations during life 
in the normal population may also be responsible for the 
increase in individuals with FDB. A very unstable phase 
in these individuals seems to be the postpubertal period 
until the early adult age. During this period, cholesterol 
concentrations may fluctuate between normal and clearly 
elevated levels as demonstrated in affected members from 
two of the families of the volunteers. After the age of 25, 
compensatory mechanisms may weaken and individuals 
with the point mutation become hypercholesterolemic. 
The striking fluctuations during the postpubertal period 
and the distinct increase in the early twenties support the 
hypothesis that there may be either compensatory 
mechanisms to metabolize apolipoprotein B-defective 
LDL particles or that the gene product of the unaffected 
allele may be overexpressed. One of the compensatory 
mechanisms could be an increased uptake of the 
apolipoprotein E-containing IDL particles by the LDL 
receptor (which is capable of binding both apolipoprotein 
E and B) before the IDL particles are metabolized 
to LDL. The present data suggest that such mecha- 
nisms decompensate after the age of 15-25 years and 
most individuals with the mutation remain hypercho- 
lesterolemic throughout life. Nevertheless, the G-to-A 
mutation does not necessarily cause hypercholesterolemia 
and it remains to be discussed whether FDB may defined 
merely by the presence of the mutation or additionally by 
the presence of hypercholesterolemia. 
In the sample of families with hypercholesterolemia, 
data of the LRC study were first used to extrapolate the 
frequency to the general population, yielding a prevalence 
of approximately 1/420. However, the LRC population 
was not representative of the Swiss because the mean 
cholesterol values were 15.5%-19.7% higher in the Swiss 
than in the North Americans included in the LRC study 
(31, 32). Hence, data of the MONICA study were used to 
estimate the prevalence of FDB in Switzerland (Table 1). 
The prevalence of heterozygous FDB subjects of approxi- 
mately 1/240 from a sample representative of the general 
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population of Switzerland and approximately 1/190 from 
the sample of families with primary hypercholesterolemia 
and thus, a prevalence of 1/209 based on the results from 
both samples, was very similar to the final frequency of a 
gene that is fixed in a population (1/204) but was higher 
than has been estimated in other Caucasian populations. 
However, the prevalence in other populations was calcu- 
lated particularly from hypercholesterolemic subjects. As 
the presence of the point mutation, at least in young in- 
dividuals, may not necessarily be associated with hyper- 
cholesterolemia, as it has been demonstrated in this study, 
extrapolations from hypercholesterolemic subjects may 
lead to an underestimation of the prevalence in the 
general population. Thus, the point mutation may be 
more frequent in other populations also. On the other 
hand, FDB seems to contribute to the higher frequency of 
hypercholesterolemic subjects in Switzerland than in 
North America as not only the absolute but also the rela- 
tive frequency of FDB in hypercholesterolemic subjects 
was higher in the Swiss than in the North Americans: esti- 
mations using data of the LRC study would result in a 
prevalence of 1/420 in the Swiss whereas the prevalence in 
the North Americans using these data was 1/500 (6). 
The frequency of FDB in hypercholesterolemic subjects 
from Switzerland was compared with those from the 
United Kingdom, Germany, and Finland. Samples from 
Montreal, San Francisco, Dallas, Salzburg, Denmark, 
and Sweden were not exactly comparable with the Swiss 
data as they included both normo- and hypercholestero- 
lemic subjects or subjects with atherosclerosis. In contrast 
to FH which is estimated to occur in one of 500 subjects 
in the general population (39) and which is caused by 
more than 150 different mutations (38), the investigated 
base substitution causing FDB was much more prevalent 
than is assumed for any particular mutation (represented 
by a LDL receptor haplotype) causing FH in Switzerland 
(27). As FDB seems to be highly prevalent in Switzerland 
and because the disorder is possibly associated with 
premature coronary artery disease (5), testing for FDB 
using PCR-based methods may therefore become a stan- 
dard procedure in the differential diagnosis of patients 
with familial forms of hypercholesterolemia. I 
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